Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease

End-stage renal disease (ESRD) patients have an excess cardiovascular risk, above that predicted by traditional risk factor models. Prothrombotic status may contribute to this increased risk. Global thrombotic status assessment, including measurement of occlusion time (OT) and thrombolytic status, may identify vulnerable patients. Our aim was to assess overall thrombotic status in ESRD and relate this to cardiovascular risk. Thrombotic and thrombolytic status of ESRD patients (n 216) on haemodialysis was assessed using the Global Thrombosis Test. This novel, near-patient test measures the time required to form (OT) and time required to lyse (lysis time, LT) an occlusive platelet thrombus. Patients were followed-up for 276 166 days for major adverse cardiovascular events (MACE, composite of cardiovascular death, non-fatal MI, or stroke). Peripheral arterial or arterio-venous fistula thrombosis was a secondary endpoint. Occlusion time was reduced (491 177 vs. 378 96 s, P 0.001) and endogenous thrombolysis was impaired (LT median 1820 vs.1053 s, P 0.001) in ESRD compared with normal subjects. LT epsilon 3000 s occurred in 42 of ESRD patients, and none of the controls. Impaired endogenous thrombolysis (LT epsilon 3000 s) was strongly associated MACE (HR 4.25, 95 CI 1.5811.46, P 0.004), non-fatal MI and stroke (HR 14.28, 95 CI 1.86109.90, P 0.01), and peripheral thrombosis (HR 9.08, 95 CI 2.0839.75, P 0.003). No association was found between OT and MACE. Impaired endogenous thrombolysis is a novel risk factor in ESRD, strongly associated with cardiovascular events.